Don't miss

Replay


LATEST SHOWS

REPORTERS

The booming business of cannabis in Spain

Read more

EYE ON AFRICA

Tanzanian President dismisses almost 10,000 public servants over forged college certificates

Read more

MEDIAWATCH

French Election: Abstention, Anger & Apathy

Read more

THE WORLD THIS WEEK

Macron vs. Le Pen: France's bitter presidential run-off race (part 1)

Read more

THE WORLD THIS WEEK

Trump's First 100 Days, The Pope in Egypt (part 2)

Read more

FOCUS

Egypt's Coptic Christians targeted by Islamic State group

Read more

THE CAMPAIGN BEAT

France's wartime past takes centre stage in presidential campaign

Read more

#TECH 24

How one NGO is using 3D printers to improve disaster relief

Read more

REVISITED

What remains of Nicaragua’s revolution?

Read more

Cancer drug may help avert transplant rejection

Latest update : 2008-12-27

The bortezomib, a cancer treatment drug, has been tested successfully on several patients whose bodies had been rejecting transplanted organs, an American study found, concluding to "significant implications for transplantation."

AFP - A drug used to treat cancer has proven effective at stopping the body from rejecting a transplanted organ when other treatments failed, a study published Saturday found.
  
US researchers administered the drug, bortezomib, to six patients whose immune systems were attacking transplanted kidneys and who did not respond to traditional anti-rejection treatments.
  
In each case, the drug promptly reversed the rejection, improved organ function, provided prolonged reductions in antibody levels and suppressed recurrent rejection for at least five months.
  
"This has significant implications for transplantation and auto immune disease," said study co-author Steve Woodle, chief of transplant surgery at the University of Cincinnati in Ohio.
  
Woodle's team is currently conducting four clinical trials to expand upon these preliminary findings.
  
The drug's side effects proved to be both predictable and manageable and toxicity levels were much less than those associated with other anti-cancer agents, the study found.
  
"We are pleased to see its toxicities are similar in transplant recipients suffering from treatment-resistant mixed organ rejection," said study co-author Jason Everly, an oncology pharmacist at the University of Cincinnati.
  
"We hope it will be a viable therapeutic treatment option in this patient group."
  
Previous studies had found that B-cells play a large role in organ rejection by making immune proteins that attack transplants.
  
The drug targets these antibody-producing plasma cells and had been shown to suppress transplant rejection in the laboratory before Woodle and his team tested it on patients.
  
The study was published in the journal Transplantation.

Date created : 2008-12-27

COMMENT(S)